A PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF THE FLT3 INHIBITOR GILTERITINIB (ASP2215) ADMINISTERED AS MAINTENANCE THERAPY FOLLOWING INDUCTION/CONSOLIDATION THERAPY FOR SUBJECTS WITH FLT3/ITD AML IN FIRST COMPLETE REMISSION
2016-001643-39LEUCEMIA MIELOIDE AGUDAFundación Jiménez DíazInvestigador: LOPEZ LORENZO JOSE LUIS
